view company updates
perform investment research
join events & discussions
ABOUT OUR MEMBERSHIPS
Redeye spoke with Martin Welschof, CEO of BioInvent, regarding the new promising data for its lead cancer program BI-1206.
By clicking "Sign up" you indicate that you read and agree to our Terms & Conditions